These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 25275138)

  • 1. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
    Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
    MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
    Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
    PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.
    Quiroz JA; Malonis RJ; Thackray LB; Cohen CA; Pallesen J; Jangra RK; Brown RS; Hofmann D; Holtsberg FW; Shulenin S; Nyakatura EK; Durnell LA; Rayannavar V; Daily JP; Ward AB; Aman MJ; Dye JM; Chandran K; Diamond MS; Kielian M; Lai JR
    PLoS Pathog; 2019 Nov; 15(11):e1008061. PubMed ID: 31697791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.
    Smith SA; Silva LA; Fox JM; Flyak AI; Kose N; Sapparapu G; Khomandiak S; Ashbrook AW; Kahle KM; Fong RH; Swayne S; Doranz BJ; McGee CE; Heise MT; Pal P; Brien JD; Austin SK; Diamond MS; Dermody TS; Crowe JE
    Cell Host Microbe; 2015 Jul; 18(1):86-95. PubMed ID: 26159721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.
    Malonis RJ; Earnest JT; Kim AS; Angeliadis M; Holtsberg FW; Aman MJ; Jangra RK; Chandran K; Daily JP; Diamond MS; Kielian M; Lai JR
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.
    Fox JM; Long F; Edeling MA; Lin H; van Duijl-Richter MKS; Fong RH; Kahle KM; Smit JM; Jin J; Simmons G; Doranz BJ; Crowe JE; Fremont DH; Rossmann MG; Diamond MS
    Cell; 2015 Nov; 163(5):1095-1107. PubMed ID: 26553503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.
    Chua CL; Sam IC; Merits A; Chan YF
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004960. PubMed ID: 27571254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel multi-epitope vaccine based on capsid and envelope protein against Chikungunya virus.
    Ma S; Zhu F; Wen H; Rao M; Zhang P; Peng W; Cui Y; Yang H; Tan C; Chen J; Pan P
    J Biomol Struct Dyn; 2024 Aug; 42(13):7024-7036. PubMed ID: 37526203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.
    Hunt AR; Frederickson S; Maruyama T; Roehrig JT; Blair CD
    PLoS Negl Trop Dis; 2010 Jul; 4(7):e739. PubMed ID: 20644615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
    Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
    PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein.
    Chua CL; Chan YF; Sam IC
    J Virol Methods; 2014 Jan; 195():126-33. PubMed ID: 24134938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
    Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
    J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.
    Pal P; Dowd KA; Brien JD; Edeling MA; Gorlatov S; Johnson S; Lee I; Akahata W; Nabel GJ; Richter MK; Smit JM; Fremont DH; Pierson TC; Heise MT; Diamond MS
    PLoS Pathog; 2013; 9(4):e1003312. PubMed ID: 23637602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.
    Jin J; Liss NM; Chen DH; Liao M; Fox JM; Shimak RM; Fong RH; Chafets D; Bakkour S; Keating S; Fomin ME; Muench MO; Sherman MB; Doranz BJ; Diamond MS; Simmons G
    Cell Rep; 2015 Dec; 13(11):2553-2564. PubMed ID: 26686638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
    Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
    EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice.
    Weber C; Büchner SM; Schnierle BS
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003684. PubMed ID: 25905779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.
    Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA
    J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
    Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
    mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.